论文部分内容阅读
目的观察美沙拉嗪联合益生菌治疗溃疡性结肠炎的临床疗效,进一步为临床治疗提供参考依据。方法将我院自2009年1月~2011年1月收治的76例确诊的溃疡性结肠炎患者随机分为联合组(美沙拉嗪联合益生菌治疗+常规治疗)和对照组(常规治疗)各38例,比较分析治疗后两组患者的疗效及不良反应情况。结果治疗4周后,根据疗效标准显示,联合组的总有效率达94.74%以上,对照组的有效率达78.95%,两组总有效率经χ2检验处理,差异有显著性(P<0.05)。两组患者治疗前后肝肾功能均未见明显异常。结论美沙拉嗪联合益生菌治疗溃疡性结肠炎疗效确切,不良反应少,值得临床推广和应用。
Objective To observe the clinical efficacy of mesalazine combined with probiotics in the treatment of ulcerative colitis and to provide reference for clinical treatment. Methods A total of 76 patients with ulcerative colitis diagnosed in our hospital from January 2009 to January 2011 were randomly divided into the combined group (mesalazine and probiotics combined with conventional therapy) and the control group (conventional therapy) 38 cases, comparative analysis of two groups of patients after treatment efficacy and adverse reactions. Results After 4 weeks of treatment, the total effective rate was 94.74% in the combined group and 78.95% in the control group. The total effective rate was significantly higher in the two groups (χ2 test, P <0.05) . Two groups of patients before and after treatment of liver and kidney function were no significant abnormalities. Conclusion Mesalazine combined with probiotics for the treatment of ulcerative colitis is effective and has few adverse reactions. It is worthy of clinical application and promotion.